Kristina Jankovic, MD路 @JankovicK 路 X路路 1 day agoScore70
Body
#TALENT at #ESMO26 馃嚜馃嚫 : neoadjuvant T-DXd alone, T-DXd + anastrozole, or T-DXd followed by TC showed high response rates but pCR <10% across all arms in HR+/HER2-low early #BreastCancer
Better biomarkers are needed to guide patient selection.
@OncoAlert
264 views 路 4 likes 路 4 reposts 路 1 reply
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgReplies in this thread
- Dr. Robert@robt_heartdoc
@JankovicK @OncoAlert The quiet finding in this figure: histology and IHC status didn't track with response at all. If nothing correlates, we're treating empirically and calling it precision oncology. My interest now is the EFS data.
Source: Kristina Jankovic, MD 路 x.com